Understanding how C16orf72 helps cancer cells survive stress

Elucidating the Role of C16orf72 in the Cellular Stress Response Network

['FUNDING_FELLOWSHIP'] · NORTHWESTERN UNIVERSITY AT CHICAGO · NIH-11031976

This study is looking at a protein called C16orf72 to see how it helps cancer cells survive tough situations, like not getting enough nutrients or having genetic problems, and the findings could help develop new treatments that make cancer cells easier to target.

Quick facts

Phase['FUNDING_FELLOWSHIP']
Study typeNih_funding
SexAll
SponsorNORTHWESTERN UNIVERSITY AT CHICAGO (nih funded)
Locations1 site (CHICAGO, UNITED STATES)
Trial IDNIH-11031976 on ClinicalTrials.gov

What this research studies

This research investigates the role of a protein called C16orf72 in helping cancer cells withstand various stressors, such as nutrient shortages and genetic abnormalities. By studying how C16orf72 interacts with other proteins involved in stress responses, the research aims to uncover the mechanisms that allow cancer cells to thrive despite challenging conditions. The approach includes analyzing cancer cell lines to identify how these stress resilience pathways work together, which could lead to new insights into cancer treatment. Patients may benefit from this research as it could reveal new targets for therapies that make cancer cells more vulnerable to treatment.

Who could benefit from this research

Good fit: Ideal candidates for this research are patients with various types of cancer, particularly those who may be experiencing treatment resistance.

Not a fit: Patients with non-cancerous conditions or those whose cancers are not characterized by stress resilience mechanisms may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to new therapeutic strategies that enhance the effectiveness of cancer treatments by targeting stress resilience mechanisms in tumor cells.

How similar studies have performed: Other research has shown success in targeting stress response pathways in cancer, suggesting that this approach may yield valuable insights and potential breakthroughs.

Where this research is happening

CHICAGO, UNITED STATES

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.

View on NIH RePORTER →

Conditions: Breast Cancer, Breast Cancer Cell, Breast Cancer Model, Breast Cancer therapy

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.